Gyeonggi-do

Futó vizsgálatok

• Toboroz

  Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  NCT07851025· 3. fázis· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

  NCT07664553· 3. fázis· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· 3. fázis· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· 3. fázis· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· Forrás

• Toboroz

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· 3. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· Forrás

• Toboroz

  Real-World Treatment Study of Koselugo (Selumetinib)

  NCT06360406· Forrás

• Fut, nem toboroz

  Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

  NCT06291376· 3. fázis· Forrás

• Fut, nem toboroz

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· 3. fázis· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Toboroz

  AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  NCT06219941· 2. fázis· Forrás

• Toboroz

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

  NCT05526755· 2. fázis· Forrás

• Fut, nem toboroz

  Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  NCT05261399· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

  NCT05048797· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· 1. fázis· Forrás

• Fut, nem toboroz

  A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

  NCT02972840· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• 2-es típusú cukorbetegség3 toboroz
• Máj- és epeúti rák3 toboroz
• Gyermekkori daganatok2 toboroz
• Gyomor- és nyelőcsőrák2 toboroz
• Elhízás1 toboroz
• Fej-nyaki daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Méhnyakrák1 toboroz
• Petefészekrák1 toboroz
• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

  NCT06020014· 2. fázis· Forrás

• Lezárult

  QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

  NCT05160974· Forrás

• Lezárult

  Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS

  NCT03918304· Forrás